Recent changes in prostate cancer screening practices and epidemiology

Journal of Urology

Volumn 198, Issue 6, 2017, Pages 1230-1240

  Lee, Daniel J ^a   Mallin, Katherine ^c   Graves, Amy J ^b   Chang, Sam S ^a   Penson, David F ^b   Resnick, Matthew J ^b   Barocas, Daniel A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c AMERICAN COLLEGE OF SURGEONS   (United States)

Author keywords

Early detection of cancer; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLOOD; EARLY CANCER DIAGNOSIS; FORECASTING; HUMAN; MALE; PRACTICE GUIDELINE; PROCEDURES; PROSTATE TUMOR; TRENDS;

EARLY DETECTION OF CANCER; FORECASTING; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 85031754473     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2017.05.074     Document Type: Review

References (50)

1. Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7.
2. Moyer VA and US Preventive Services Task Force: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120.
3. U.S. Preventive Services Task Force: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 185.
4. Carter HB, Albertsen PC, Barry MJ et al: Early detection of prostate cancer: AUA guideline. J Urol 2013; 190: 419.
5. Tasian GE, Cooperberg MR, Cowan JE et al: Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians. Urol Oncol 2012; 30: 155.
6. Gulati R, Gore JL and Etzioni R: Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med 2013; 158: 145.
7. Canto EI, Shariat SF and Slawin KM: Biochemical staging of prostate cancer. Urol Clin North Am 2003; 30: 263.
8. Colorectal Cancer Collaborative Group: Surgery for colorectal cancer in elderly patients: a systematic review. Colorectal Cancer Collaborative Group. Lancet 2000; 356: 968.
9. Bill-Axelson A, Holmberg L, Filén F et al: Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial. J Natl Cancer Inst 2008; 100: 1144.
10. Pound CR, Partin AW, Eisenberger MA et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591.
11. Wilt TJ, Brawer MK, Jones KM et al: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203.
12. Drazer MW, Prasad SM, Huo D et al: National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer 2014; 120: 1491.
13. Prasad SM, Drazer MW, Huo D et al: 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA 2012; 307: 1692.
14. Scosyrev E, Wu G, Golijanin D et al: Prostatespecific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system. BJU Int 2012; 110: 1485.
15. Jemal A, Fedewa SA, Ma J et al: Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 2015; 314: 2054.
16. Goodwin JS, Jaramillo E, Yang L et al: Is anyone listening? Variation in PSA screening among providers for men 75+ before and after United States Preventive Services Task Force recommendations against it: a retrospective cohort study. PLoS One 2014; 9: e107352.
17. Lee SY, Friderici J, Stefan MS et al: Impact of the 2008 U.S. Preventative Services Task Force recommendation on frequency of prostatespecific antigen screening in older men. J Am Geriatr Soc 2014; 62: 1912.
18. Howard DH, Tangka FK, Guy GP et al: Prostate cancer screening in men ages 75 and older fell by 8 percentage points after Task Force recommendation. Health Aff (Millwood) 2013; 32: 596.
19. Cohn JA, Wang CE, Lakeman JC et al: Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation. Urol Oncol 2014; 32: 41.e23.
20. Zeliadt SB, Hoffman RM, Etzioni R et al: Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst 2011; 103: 520.
21. Aslani A, Minnillo BJ, Johnson B et al: The impact of recent screening recommendations on prostate cancer screening in a large health care system. J Urol 2014; 191: 1737.
22. Howard DH: Declines in prostate cancer incidence after changes in screening recommendations. Arch Intern Med 2012; 172: 1267.
23. Li J, Berkowitz Z and Hall IJ: Decrease in prostate cancer testing following the US Preventive Services Task Force (USPSTF) recommendations. J Am Board Fam Med 2015; 28: 491.
24. Sammon JD, Abdollah F, Choueiri TK et al: Prostate-specific antigen screening after 2012 US Preventive Services Task Force recommendations. JAMA 2015; 314: 2077.
25. Drazer MW, Huo D and Eggener SE: National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigenbased screening. J Clin Oncol 2015; 33: 2416.
26. Kim SP, Karnes RJ, Gross CP et al: Contemporary national trends of prostate cancer screening among privately insured men in the United States. Urology 2016; 97: 111.
27. Zavaski ME, Meyer CP, Sammon JD et al: Differences in prostate-specific antigen testing among urologists and primary care physicians following the 2012 USPSTF recommendations. JAMA Intern Med 2016; 176: 546.
28. Shoag J, Halpern JA, Lee DJ et al: Decline in prostate cancer screening by primary care physicians: an analysis of trends in the use of digital rectal examination and prostate specific antigen testing. J Urol 2016; 196: 1047.
29. Hutchinson R, Akhtar A, Haridas J et al: Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening. Cancer 2016; 122: 3785.
30. Gershman B, Van Houten HK, Herrin J et al: Impact of prostate-specific antigen (PSA) screening trials and revised PSA screening guidelines on rates of prostate biopsy and postbiopsy complications. Eur Urol 2017; 71: 55.
31. Banerji JS, Wolff EM, Massman JD III et al: Prostate needle biopsy outcomes in the era of the U.S. Preventive Services Task Force recommendation against prostate specific antigen based screening. J Urol 2016; 195: 66.
32. Bhindi B, Mamdani M, Kulkarni GS et al: Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates. J Urol 2015; 193: 1519.
33. Perez TY, Danzig MR, Ghandour RA et al: Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices. Urology 2015; 85: 85.
34. McGinley KF, McMahon GC and Brown GA: Impact of the US Preventive Services Task Force grade D recommendation: assessment of evaluations for elevated prostate-specific antigen and prostate biopsies in a large urology group practice following statement revision. Rev Urol 2015; 17: 171.
35. Halpern JA, Shoag JE, Artis AS et al: National trends in prostate biopsy and radical prostatectomy volumes following the US Preventive Services Task Force guidelines against prostatespecific antigen screening. JAMA Surg 2017; 152: 192.
36. Barocas DA, Mallin K, Graves AJ et al: Effect of the USPSTF grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the United States. J Urol 2015; 194: 1587.
37. Herget KA, Patel DP, Hanson HA et al: Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score. Cancer Med 2016; 5: 136.
38. Reese AC, Wessel SR, Fisher SG et al: Evidence of prostate cancer "reverse stage migration" toward more advanced disease at diagnosis: data from the Pennsylvania Cancer Registry. Urol Oncol 2016; 34: 335.e21.
39. Gulati R, Tsodikov A, Etzioni R et al: Expected population impacts of discontinued prostatespecific antigen screening. Cancer 2014; 120: 3519.
40. Weiner AB, Matulewicz RS, Eggener SE et al: Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis 2016; 19: 395.
41. American Cancer Society Pressroom Blog: When 'skyrocketing' isn't. July 19, 2016. Available at https://acspressroom.wordpress.com/2016/07/19/ when-skyrocketing-isnt/. Accessed December 1, 2016.
42. Bilimoria KY, Stewart AK, Winchester DP et al: The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 2008; 15: 683.
43. North American Association of Central Cancer Registries: Rate ofmetastatic prostate cancer is not increasing. July 27, 2016. Available at http://news. naaccr.org/rate-of-metastatic-prostate-cancer-isnot- increasing. Accessed December 1, 2016.
44. Jemal A, Ma J, Siegel R et al: Prostate cancer incidence rates 2 years after the US Preventive Services Task Force recommendations against screening. JAMA Oncol 2016; 2: 1657.
45. Hu JC, Nguyen P, Mao J et al: Increase in prostate cancer distant metastases at diagnosis in the United States. JAMA Oncol 2017; 3: 705.
46. Eggener S: Prostate cancer screening biomarkers: an emerging embarrassment of 'riches'? Eur Urol 2016; 70: 54.
47. Wysock JS, Mendhiratta N, Zattoni F et al: Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results. BJU Int 2016; 118: 515.
48. Womble PR, Montie JE, Ye Z et al: Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol 2015; 67: 44.
49. Vickers AJ, Ulmert D, Sjoberg DD et al: Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: casecontrol study. BMJ 2013; 346: f2023.
50. U.S. Preventive Services Task Force: Draft Recommendation Statement: Prostate Cancer: Screening. April 2017. Available at https://www. uspreventiveservicestaskforce.org/Page/Document/ draft-recommendation-statement/prostate-cancerscreening1. Accessed December 1, 2016.